{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:36:23Z","timestamp":1790807783129,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature Nanotech"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1038\/nnano.2016.135","type":"journal-article","created":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T12:00:46Z","timestamp":1469793646000},"page":"890-899","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":196,"title":["Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles"],"prefix":"10.1038","volume":"11","author":[{"given":"Takashi K.","family":"Kishimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"LaMothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi N.","family":"Kolte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron P.","family":"Griset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conlin","family":"O'Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Browning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Chalishazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Kuhlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen-ni","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Viseux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Altreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto A.","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,1]]},"reference":[{"key":"BFnnano2016135_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nrd3040","volume":"8","author":"M Goodman","year":"2009","unstructured":"Goodman, M. Market watch: sales of biologics to show robust growth through to 2013. Nat. Rev. Drug Discov. 8, 837 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnnano2016135_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nrd3974","volume":"12","author":"JG Sathish","year":"2013","unstructured":"Sathish, J. G. et al. Challenges and approaches for the development of safer immunomodulatory biologics. Nat. Rev. Drug Discov. 12, 306\u2013324 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnnano2016135_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","volume":"9","author":"PA van Schouwenburg","year":"2013","unstructured":"van Schouwenburg, P. A., Rispens, T. & Wolbink, G. J. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat. Rev. Rheumatol. 9, 164\u2013172 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnnano2016135_CR4","first-page":"15","volume":"112","author":"AS Rosenberg","year":"2003","unstructured":"Rosenberg, A. S. Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev. Biol. 112, 15\u201321 (2003).","journal-title":"Dev. Biol."},{"key":"BFnnano2016135_CR5","first-page":"560","volume":"9","author":"H Schellekens","year":"2010","unstructured":"Schellekens, H. The immunogenicity of therapeutic proteins. Discov. Med. 9, 560\u2013564 (2010).","journal-title":"Discov. Med."},{"key":"BFnnano2016135_CR6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","volume":"14","author":"N Chirmule","year":"2012","unstructured":"Chirmule, N., Jawa, V. & Meibohm, B. Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy. AAPS J. 14, 296\u2013302 (2012).","journal-title":"AAPS J."},{"key":"BFnnano2016135_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1056\/NEJMoa011931","volume":"346","author":"N Casadevall","year":"2002","unstructured":"Casadevall, N. et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346, 469\u2013475 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnnano2016135_CR8","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/gim.2015.6","volume":"17","author":"KL Berrier","year":"2015","unstructured":"Berrier, K. L. et al. CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. Genet. Med. 17, 912\u2013918 (2015).","journal-title":"Genet. Med."},{"key":"BFnnano2016135_CR9","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds, G. M. et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305, 1460\u20131468 (2011).","journal-title":"JAMA"},{"key":"BFnnano2016135_CR10","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s11095-013-1067-7","volume":"30","author":"H Schellekens","year":"2013","unstructured":"Schellekens, H., Hennink, W. E. & Brinks, V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm. Res. 30, 1729\u20131734 (2013).","journal-title":"Pharm. Res."},{"key":"BFnnano2016135_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1001\/jama.2011.1617","volume":"306","author":"JS Sundy","year":"2011","unstructured":"Sundy, J. S. et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 306, 711\u2013720 (2011).","journal-title":"JAMA"},{"key":"BFnnano2016135_CR12","doi-asserted-by":"publisher","first-page":"R60","DOI":"10.1186\/ar4497","volume":"16","author":"PE Lipsky","year":"2014","unstructured":"Lipsky, P. E. et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res. Ther. 16, R60 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"BFnnano2016135_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1208\/s12248-014-9587-6","volume":"16","author":"A Parenky","year":"2014","unstructured":"Parenky, A. et al. New FDA draft guidance on immunogenicity. AAPS J. 16, 499\u2013503 (2014).","journal-title":"AAPS J."},{"key":"BFnnano2016135_CR14","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nrrheum.2010.153","volume":"6","author":"CL Krieckaert","year":"2010","unstructured":"Krieckaert, C. L., Bartelds, G. M. & Wolbink, G. J. Therapy: Immunogenicity of biologic therapies-we need tolerance. Nat. Rev. Rheumatol. 6, 558\u2013559 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnnano2016135_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/B978-0-12-380995-7.00004-5","volume":"108","author":"RA Maldonado","year":"2010","unstructured":"Maldonado, R. A. & von Andrian, U. H. How tolerogenic dendritic cells induce regulatory T cells. Adv. Immunol. 108, 111\u2013165 (2010).","journal-title":"Adv. Immunol."},{"key":"BFnnano2016135_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1479-5876-9-89","volume":"9","author":"M Naranjo-Gomez","year":"2011","unstructured":"Naranjo-Gomez, M. et al. Comparative study of clinical grade human tolerogenic dendritic cells. J. Transl. Med. 9, 89 (2011).","journal-title":"J. Transl. Med."},{"key":"BFnnano2016135_CR17","doi-asserted-by":"crossref","unstructured":"Fischer, R., Turnquist, H. R., Taner, T. & Thomson, A. W. Use of rapamycin in the induction of tolerogenic dendritic cells. Handb Exp Pharmacol, 215\u2013232 (2009).","DOI":"10.1007\/978-3-540-71029-5_10"},{"key":"BFnnano2016135_CR18","doi-asserted-by":"publisher","first-page":"E156","DOI":"10.1073\/pnas.1408686111","volume":"112","author":"RA Maldonado","year":"2015","unstructured":"Maldonado, R. A. et al. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc. Natl Acad. Sci. USA 112, E156\u2013E165 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnnano2016135_CR19","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1073\/pnas.91.2.742","volume":"91","author":"X Wu","year":"1994","unstructured":"Wu, X. et al. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc. Natl Acad. Sci. USA 91, 742\u2013746 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnnano2016135_CR20","doi-asserted-by":"publisher","first-page":"e0125078","DOI":"10.1371\/journal.pone.0125078","volume":"10","author":"LA Haile","year":"2015","unstructured":"Haile, L. A., Puig, M., Kelley-Baker, L. & Verthelyi, D. Detection of innate immune response modulating impurities in therapeutic proteins. PLoS ONE 10, e0125078 (2015).","journal-title":"PLoS ONE"},{"key":"BFnnano2016135_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1365-2249.2008.03602.x","volume":"152","author":"A Joseph","year":"2008","unstructured":"Joseph, A., Munroe, K., Housman, M., Garman, R. & Richards, S. Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin. Exp. Immunol. 152, 138\u2013146 (2008).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnnano2016135_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1046\/j.1440-1711.1998.00709.x","volume":"76","author":"MJ Barnden","year":"1998","unstructured":"Barnden, M. J., Allison, J., Heath, W. R. & Carbone, F. R. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol. Cell. Biol. 76, 34\u201340 (1998).","journal-title":"Immunol. Cell. Biol."},{"key":"BFnnano2016135_CR23","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.immuni.2006.10.017","volume":"25","author":"KT Merrell","year":"2006","unstructured":"Merrell, K. T. et al. Identification of anergic B cells within a wild-type repertoire. Immunity 25, 953\u2013962 (2006).","journal-title":"Immunity"},{"key":"BFnnano2016135_CR24","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.immuni.2014.10.016","volume":"41","author":"M Matsumoto","year":"2014","unstructured":"Matsumoto, M. et al. Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation. Immunity 41, 1040\u20131051 (2014).","journal-title":"Immunity"},{"key":"BFnnano2016135_CR25","first-page":"1942","volume":"29","author":"JS Bomalaski","year":"2002","unstructured":"Bomalaski, J. S., Holtsberg, F. W., Ensor, C. M. & Clark, M. A. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J. Rheumatol. 29, 1942\u20131949 (2002).","journal-title":"J. Rheumatol."},{"key":"BFnnano2016135_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1472-6793-7-13","volume":"7","author":"MD Hayward","year":"2007","unstructured":"Hayward, M. D. et al. An extensive phenotypic characterization of the hTNFalpha transgenic mice. BMC Physiol. 7, 13 (2007).","journal-title":"BMC Physiol."},{"key":"BFnnano2016135_CR27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nri2356","volume":"8","author":"JA Hamilton","year":"2008","unstructured":"Hamilton, J. A. Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol. 8, 533\u2013544 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnnano2016135_CR28","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/nmat3775","volume":"12","author":"DJ Irvine","year":"2013","unstructured":"Irvine, D. J., Swartz, M. A. & Szeto, G. L. Engineering synthetic vaccines using cues from natural immunity. Nature Mater. 12, 978\u2013990 (2013).","journal-title":"Nature Mater."},{"key":"BFnnano2016135_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmed.2011.11.002","volume":"18","author":"SM Metcalfe","year":"2012","unstructured":"Metcalfe, S. M. & Fahmy, T. M. Targeted nanotherapy for induction of therapeutic immune responses. Trends Mol. Med. 18, 72\u201380 (2012).","journal-title":"Trends Mol. Med."},{"key":"BFnnano2016135_CR30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","volume":"10","author":"MF Bachmann","year":"2010","unstructured":"Bachmann, M. F. & Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787\u2013796 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnnano2016135_CR31","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1002\/eji.200737281","volume":"37","author":"AC Donahue","year":"2007","unstructured":"Donahue, A. C. & Fruman, D. A. Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuli. Eur. J. Immunol. 37, 2923\u20132936 (2007).","journal-title":"Eur. J. Immunol."},{"key":"BFnnano2016135_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3389\/fimmu.2012.00228","volume":"3","author":"JJ Limon","year":"2012","unstructured":"Limon, J. J. & Fruman, D. A. Akt and mTOR in B cell activation and differentiation. Front. Immunol. 3, 228 (2012).","journal-title":"Front. Immunol."},{"key":"BFnnano2016135_CR33","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/ni.2741","volume":"14","author":"R Keating","year":"2013","unstructured":"Keating, R. et al. The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nature Immunol. 14, 1266\u20131276 (2013).","journal-title":"Nature Immunol."},{"key":"BFnnano2016135_CR34","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jtcvs.2015.08.116","volume":"151","author":"Y Zhao","year":"2016","unstructured":"Zhao, Y. et al. Rapamycin prevents bronchiolitis obliterans through increasing infiltration of regulatory B cells in a murine tracheal transplantation model. J. Thorac. Cardiovasc. Surg. 151, 487\u2013496 (2016).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"BFnnano2016135_CR35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jconrel.2011.10.037","volume":"161","author":"G Pasut","year":"2012","unstructured":"Pasut, G. & Veronese, F. M. State of the art in PEGylation: the great versatility achieved after forty years of research. J. Control. Release 161, 461\u2013472 (2012).","journal-title":"J. Control. Release"},{"key":"BFnnano2016135_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/cncr.22739","volume":"110","author":"JK Armstrong","year":"2007","unstructured":"Armstrong, J. K. et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110, 103\u2013111 (2007).","journal-title":"Cancer"},{"key":"BFnnano2016135_CR37","first-page":"171","volume":"122","author":"AS De Groot","year":"2005","unstructured":"De Groot, A. S., Knopp, P. M. & Martin, W. De-immunization of therapeutic proteins by T-cell epitope modification. Dev. Biol. 122, 171\u2013194 (2005).","journal-title":"Dev. Biol."},{"key":"BFnnano2016135_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11318560-000000000-00000","volume":"24","author":"CJ Bryson","year":"2010","unstructured":"Bryson, C. J., Jones, T. D. & Baker, M. P. Prediction of immunogenicity of therapeutic proteins: validity of computational tools. BioDrugs 24, 1\u20138 (2010).","journal-title":"BioDrugs"},{"key":"BFnnano2016135_CR39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2174\/138945009787354511","volume":"10","author":"M Onda","year":"2009","unstructured":"Onda, M. Reducing the immunogenicity of protein therapeutics. Curr. Drug Targets 10, 131\u2013139 (2009).","journal-title":"Curr. Drug Targets"},{"key":"BFnnano2016135_CR40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jim.2015.06.003","volume":"425","author":"R Mazor","year":"2015","unstructured":"Mazor, R., Tai, C. H., Lee, B. & Pastan, I. Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A. J. Immunol. Methods 425, 10\u201320 (2015).","journal-title":"J. Immunol. Methods"},{"key":"BFnnano2016135_CR41","doi-asserted-by":"publisher","first-page":"8571","DOI":"10.1073\/pnas.1405153111","volume":"111","author":"R Mazor","year":"2014","unstructured":"Mazor, R. et al. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. Proc. Natl Acad. Sci. USA 111, 8571\u20138576 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnnano2016135_CR42","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.4049\/jimmunol.1401723","volume":"193","author":"MS Macauley","year":"2014","unstructured":"Macauley, M. S. & Paulson, J. C. Siglecs induce tolerance to cell surface antigens by BIM-dependent deletion of the antigen-reactive B cells. J. Immunol. 193, 4312\u20134321 (2014).","journal-title":"J. Immunol."},{"key":"BFnnano2016135_CR43","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/hae.12407","volume":"20","author":"DW Scott","year":"2014","unstructured":"Scott, D. W. Inhibitors \u2013 cellular aspects and novel approaches for tolerance. Haemophilia 20(Suppl 4), 80\u201386 (2014).","journal-title":"Haemophilia"},{"key":"BFnnano2016135_CR44","doi-asserted-by":"publisher","first-page":"e1500112","DOI":"10.1126\/sciadv.1500112","volume":"1","author":"KM Lorentz","year":"2015","unstructured":"Lorentz, K. M., Kontos, S., Diaceri, G., Henry, H. & Hubbell, J. A. Engineered binding to erythrocytes induces immunological tolerance to E. coli asparaginase. Sci. Adv. 1, e1500112 (2015).","journal-title":"Sci. Adv."},{"key":"BFnnano2016135_CR45","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.4049\/jimmunol.162.6.3663","volume":"162","author":"LK Gilliland","year":"1999","unstructured":"Gilliland, L. K. et al. Elimination of the immunogenicity of therapeutic antibodies. J. Immunol. 162, 3663\u20133671 (1999).","journal-title":"J. Immunol."},{"key":"BFnnano2016135_CR46","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1182\/blood.V96.5.1698","volume":"96","author":"AB Colowick","year":"2000","unstructured":"Colowick, A. B., Bohn, R. L., Avorn, J. & Ewenstein, B. M. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 96, 1698\u20131702 (2000).","journal-title":"Blood"},{"key":"BFnnano2016135_CR47","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1056\/NEJMc0806809","volume":"360","author":"NJ Mendelsohn","year":"2009","unstructured":"Mendelsohn, N. J., Messinger, Y. H., Rosenberg, A. S. & Kishnani, P. S. Elimination of antibodies to recombinant enzyme in Pompe's disease. N. Engl. J. Med. 360, 194\u2013195 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnnano2016135_CR48","unstructured":"Safety and Pharmacodynamics of SEL-212 (Pegsiticase+SEL-110) in Subjects With Elevated Blood Uric Acid Levels. ClinicalTrials.gov. http:\/\/dx.doi.org\/NCT02648269 ."},{"key":"BFnnano2016135_CR49","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1163\/156856206775997322","volume":"17","author":"CE Astete","year":"2006","unstructured":"Astete, C. E. & Sabliov, C. M. Synthesis and characterization of PLGA nanoparticles. J. Biomater. Sci. Polym. Ed. 17, 247\u2013289 (2006).","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"BFnnano2016135_CR50","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1172\/JCI0215488","volume":"110","author":"E Liu","year":"2002","unstructured":"Liu, E. et al. Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. J. Clin. Invest. 110, 1021\u20131027 (2002).","journal-title":"J. Clin. Invest."}],"container-title":["Nature Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nnano.2016.135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nnano.2016.135","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nnano.2016.135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T11:58:45Z","timestamp":1692446325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nnano.2016.135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,1]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["BFnnano2016135"],"URL":"https:\/\/doi.org\/10.1038\/nnano.2016.135","relation":{},"ISSN":["1748-3387","1748-3395"],"issn-type":[{"value":"1748-3387","type":"print"},{"value":"1748-3395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,1]]},"assertion":[{"value":"15 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are employees and shareholders of Selecta Biosciences.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}